Results 11 to 20 of about 16,373 (205)

Malaria in Bangladesh, 2000-2025: Navigating the Headwinds From Control to Elimination. [PDF]

Health Sci Rep
ABSTRACT Background and Aims Bangladesh has dramatically reduced its malaria burden since 2000, confining the disease to specific geographic zones. However, the national 2030 elimination goal is now threatened by a complex interplay of biological, ecological, and social factors.
Mamun AA, Kayenat MSA, Islam KAMI.
europepmc   +2 more sources

5-Phenoxy Primaquine Analogs and the Tetraoxane Hybrid as Antimalarial Agents

Molecules, 2021
The rapid emergence of drug resistance to the current antimalarial agents has led to the urgent need for the discovery of new and effective compounds.
Somruedee Jansongsaeng, Nitipol Srimongkolpithak, Jutharat Pengon, Sumalee Kamchonwongpaisan, Tanatorn Khotavivattana   +4 more
doaj   +1 more source

Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open-label randomized trial. [PDF]

PLoS ONE, 2017
BACKGROUND:Single low dose primaquine (SLD PQ, 0.25mg/kg) is recommended in combination with artemisinin-based combination therapy (ACT) as a gametocytocide to prevent Plasmodium falciparum transmission in areas threatened by artemisinin resistance.
Jessica T Lin, Chanthap Lon, Michele D Spring, Somethy Sok, Soklyda Chann, Mali Ittiverakul, Worachet Kuntawunginn, Mok My, Kheangheng Thay, Rifat Rahman, Sujata Balasubramanian, Mengchuor Char, Charlotte A Lanteri, Panita Gosi, Ratawan Ubalee, Steven R Meshnick, David L Saunders   +16 more
doaj   +1 more source

Formation primaquine-5,6-orthoquinone, the putative active and toxic metabolite of primaquine via direct oxidation in human erythrocytes

Malaria Journal, 2019
Background The activity and haemolytic toxicity associated with primaquine has been linked to its reactive metabolites. The reactive metabolites are thought to be primarily formed through the action of cytochrome P450-mediated pathways.
Pius S. Fasinu, N. P. Dhammika Nanayakkara, Yan-Hong Wang, Narayan D. Chaurasiya, H. M. Bandara Herath, James D. McChesney, Bharathi Avula, Ikhlas Khan, Babu L. Tekwani, Larry A. Walker   +9 more
doaj   +1 more source

KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro. [PDF]

, 2014
Preventing relapses of Plasmodium vivax malaria through a radical cure depends on use of the 8-aminoquinoline primaquine, which is associated with safety and compliance issues.
Borboa, Rachel, Campo, Brice, Chatterjee, Arnab K, Chen, Zhong, Diagana, Thierry T, Gagaring, Kerstin, Glynne, Richard J, Klooster, Els J, Kocken, Clemens HM, Kuhen, Kelli, Leroy, Didier, Luty, Adrian, McNamara, Case W, Nagle, Advait, Plouffe, David M, Remarque, Edmond J, Roland, Jason, Sauerwein, Robert, Thomas, Alan W, van Amsterdam, Sandra M, van den Berg, Alexander, van Gemert, Geert-Jan, Voorberg-van der Wel, Annemarie, Winzeler, Elizabeth A, Yeung, Bryan KS, Zeeman, Anne-Marie   +25 more
core   +1 more source

Primaquine in vivax malaria: an update and review on management issues

Malaria Journal, 2011
Primaquine was officially licensed as an anti-malarial drug by the FDA in 1952. It has remained the only FDA licensed drug capable of clearing the intra-hepatic schizonts and hypnozoites of Plasmodium vivax.
Fernando Deepika, Rodrigo Chaturaka, Rajapakse Senaka   +2 more
doaj   +1 more source

Combined DNA extraction and antibody elution from filter papers for the assessment of malaria transmission intensity in epidemiological studies. [PDF]

, 2013
BACKGROUND: Informing and evaluating malaria control efforts relies on knowledge of local transmission dynamics. Serological and molecular tools have demonstrated great sensitivity to quantify transmission intensity in low endemic settings where the ...
Baidjoe, Amrish, Bousema, Teun, Cox, Jonathan, Drakeley, Chris, Grignard, Lynn, Kariuki, Simon, Makori, Euniah, Osoti, Victor, Ploemen, Ivo, Sauerwein, Robert, Shagari, Shehu, Stevenson, Jennifer, Stone, Will, Sutherland, Colin   +13 more
core   +3 more sources

Pharmaceutical compounding of orphan active ingredients in Belgium : how community and hospital pharmacists can address the needs of patients with rare diseases [PDF]

, 2019
Background: Pharmaceutical compounding of orphan active ingredients can offer cost-effective treatment to patients when no other drug product is available for a rare disease or during periods of drug product shortages.
Boussery, Koen, De Spiegeleer, Bart, Peeters, E, Remon, Jean Paul, Van Tongelen, Inge, Vanhoorne, Valérie, Vervaet, Chris, Wynendaele, Evelien   +7 more
core   +2 more sources

Primaquine 30 mg/day versus 15 mg/day during 14 days for the prevention of Plasmodium vivax relapses in adults in French Guiana: a historical comparison

Malaria Journal, 2018
Background The preventive treatment of Plasmodium vivax relapse recommended by the World Health Organization is primaquine at a dose of 15 mg/day for 14 days, except for malaria cases from Asia and Oceania.
Audrey Valdes, Loic Epelboin, Emilie Mosnier, Gaelle Walter, Guillaume Vesin, Philippe Abboud, Alessia Melzani, Denis Blanchet, Nicaise Blaise, Mathieu Nacher, Magalie Demar, Felix Djossou   +11 more
doaj   +1 more source

Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries. [PDF]

PLoS Neglected Tropical Diseases, 2018
Primaquine is the only available antimalarial drug that kills dormant liver stages of Plasmodium vivax and Plasmodium ovale malarias and therefore prevents their relapse ('radical cure').
Judith Recht, Elizabeth A Ashley, Nicholas J White   +2 more
doaj   +1 more source